Abstract:Abstract Pancreatic Ductal Adenocarcinoma (PDAC) is the fourth leading cause of cancer related deaths in the US, with the lowest five-year survival rate of all major cancers. Nutrients in the PDAC microenvironment are commonly depleted, with the vital amino acid glutamine among the most deficient metabolites. To circumvent this deprivation, PDAC cells initiate KRAS dependent macropinocytosis, an actin-driven nutrient scavenging pathway. Macropinosomes fuse with lysosomes in a process mediated by the kinase PIKfyve. It allows cells to replenish the nutrients required for survival. As glutamine is essential for PDAC cell survival, therapeutic inhibition of macropinocytosis represents a novel strategy to suppress nutrient acquisition and drive cell death. Protein phosphatase 2A (PP2A) is a heterotrimeric Serine/Threonine phosphatase known to inhibit downstream targets of the KRAS signaling cascade and is implicated in macropinocytosis regulation. PP2A holoenzyme comprises of A, B and C subunits, where the regulatory B subunit provides substrate specificity to the enzyme. Using high molecular weight TMR-Dextran, we demonstrate that overexpression of PP2A-B56α subunit or pharmacological activation by DT061 promotes macropinosome accumulation in cells. Macropinosome accumulation was caused by the inability of macropinosomes to fuse with lysosomes, leading to cell death. The cell death caused by DT061 was significantly rescued when treated with a Rac family inhibitor. To understand if B56α regulates the process of macropinosome-lysosome fusion, we performed co-immunoprecipitation and established the interaction of B56α with PIKfyve. Further, pharmacological PIKfyve inhibition with Apilimod phenocopies DT061 induced vesicle accumulation in cells, suggesting that B56α likely inhibits PIKfyve to promote aberrant macropinocytosis. Prevention of lysosomal fusion will impact nutrient uptake through macropinocytosis. Our metabolomics study confirmed the deprivation of glutamine with activation of PP2A-B56α. This regulation can be therapeutically leveraged to metabolically stress cells with a combination of DT061 and glutamine transport inhibitor V-9302. Combination drug treatment was found to be synergistic in a panel of PDAC cells. Together, these findings indicate that activation of PP2A in late stage PDAC promotes aberrant macropinocytosis by preventing lysosomal fusion through PIKfyve regulation and establishes a novel role of PP2A-B56α in nutrient scavenging and cell death. These pathways can be further exploited to identify potential combination therapeutics in PDAC. Citation Format: Garima Baral, Claire M. Pfeffer, Indiraa Doraivel, Sara N. Filippelli, Brittany L. Allen-Petersen. PP2A-B56α in nutrient scavenging: Tipping the balance from macropinocytosis to cell death in pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4374.

The B56γ3-containing protein phosphatase 2A attenuates p70S6K-mediated negative feedback loop to enhance AKT-facilitated epithelial-mesenchymal transition in colorectal cancer

Protein Phosphatase-2A is a Target of Epigallocatechin-3-Gallate and Modulates P53-Bak Apoptotic Pathway

Comprehensive analysis of the protein phosphatase 2A regulatory subunit B56ε in pan-cancer and its role and mechanism in hepatocellular carcinoma

Protein Phosphatase 2a (Pp2a) Is Essential For Cd8+T Cell Mediated Anti-Tumor Immunity

PTPN3 Acts As a Tumor Suppressor and Boosts TGF-β Signaling Independent of Its Phosphatase Activity.

Protein phosphatase 6 promotes stemness of colorectal cancer cells

Akt2 Overexpression Plays A Critical Role in the Establishment of Colorectal Cancer Metastasis

PP2A-Mediated Anticancer Therapy.

PBK Enhances Cellular Proliferation With Histone H3 Phosphorylation and Suppresses Migration and Invasion With CDH1 Stabilization in Colorectal Cancer

Protein Phosphatase 2A Suppresses Bcl2’s Antiapoptotic Function by Regulating Bcl2-p53 Interaction

PPP2R2D, a Regulatory Subunit of Protein Phosphataseï¿½2a, Promotes Gastric Cancer Growth and Metastasis Via Mechanistic Target of Rapamycin Activation

KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development

S6K1-mediated Phosphorylation of PDK1 Impairs AKT Kinase Activity and Oncogenic Functions

Abstract 4374: PP2A-B56α in nutrient scavenging: Tipping the balance from macropinocytosis to cell death in pancreatic cancer

Protein Phosphatase 2A-B55δ Enhances Chemotherapy Sensitivity of Human Hepatocellular Carcinoma under the Regulation of Microrna-133B

Oncoprotein CIP 2A is Stabilized Via Interaction with Tumor Suppressor PP 2A/B56

Abstract A054: PP2A activation alters macropinosome processing in pancreatic cancer cells leading to metabolic stress and cancer cell death

Deregulated PP1α Phosphatase Activity Towards MAPK Activation is Antagonized by a Tumor Suppressive Failsafe Mechanism

Down-regulated Expression of PP2A Catalytic Subunit in Pancreatic Cancer Cells Promotes Cell Growth

Both Decreased and Increased SRPK1 Levels Promote Cancer by Interfering with PHLPP-Mediated Dephosphorylation of Akt